# Capecitabine in the Perioperative Treatment of Rectal Cancer

> **NCT01500993** · PHASE3 · COMPLETED · sponsor: **Universitätsmedizin Mannheim** · enrollment: 401 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT01500993
- **Lead sponsor:** Universitätsmedizin Mannheim
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500993, "Capecitabine in the Perioperative Treatment of Rectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01500993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*